{"id":"tp-60467","type":"article-newspaper","title":"Retension Pharmaceuticals Posts $7.33 Q3 GAAP Loss Per Share","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/60467","datePublished":"2026-11-18T13:40:09.000Z","dateModified":"2026-11-18T13:40:09.000Z","language":"en","abstract":"Cash and cash equivalents totaled $9.2 million at Sept. 30, excluding about $45.1 million in net IPO proceeds from a deal that closed after the quarter.","section":"Business","references":[]}